Evidence map›Paper›PMID 33673088›Full record

ReviewMolecules (Basel, Switzerland)2021

Unlocking the Secrets of Cancer Stem Cells with γ-Secretase Inhibitors: A Novel Anticancer Strategy.

Maryam Ghanbari-Movahed, Zahra Ghanbari-Movahed, Saeideh Momtaz, Kaitlyn L Kilpatrick, Mohammad Hosein Farzaei, Anupam Bishayee

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Head and neck squamous cell carcinoma: current and emerging therapeutic strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Maryam Ghanbari-MovahedMedical Technology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah 6734667149, Iran.ORCID 0000-0002-6190-0729
Zahra Ghanbari-MovahedMedical Biology Research Center, Kermanshah University of Medical sciences, Kermanshah 6714415185, Iran.ORCID 0000-0003-3353-7034
Saeideh MomtazMedicinal Plants Research Center, Institute of Medicinal Plants, Academic Center for Education, Culture and Research, Tehran 1417614411, Iran.ORCID 0000-0003-3957-3300
Kaitlyn L KilpatrickLake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA.ORCID 0000-0001-9483-4652
Mohammad Hosein FarzaeiMedical Technology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah 6734667149, Iran.ORCID 0000-0001-7081-6521
Anupam BishayeeLake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA.ORCID 0000-0001-9159-960X
Kermanshah University of Medical Sciences · IRLake Erie College of Osteopathic Medicine · USAcademic Center for Education, Culture and Research · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The dysregulation of Notch signaling is associated with a wide variety of different human cancers. Notch signaling activation mostly relies on the activity of the γ-secretase enzyme that cleaves the Notch receptors and releases the active intracellular domain. It is well-documented that γ-secretase inhibitors (GSIs) block the Notch activity, mainly by inhibiting the oncogenic activity of this pathway. To date, several GSIs have been introduced clinically for the treatment of various diseases, such as Alzheimer's disease and various cancers, and their impacts on Notch inhibition have been found to be promising. Therefore, GSIs are of great interest for cancer therapy. The objective of this review is to provide a systematic review of in vitro and in vivo studies for investigating the effect of GSIs on various cancer stem cells (CSCs), mainly by modulation of the Notch signaling pathway. Various scholarly electronic databases were searched and relevant studies published in the English language were collected up to February 2020. Herein, we conclude that GSIs can be potential candidates for CSC-targeting therapy. The outcome of our study also indicates that GSIs in combination with anticancer drugs have a greater inhibitory effect on CSCs.

Indexed as

Amyloid Precursor Protein SecretasesAntineoplastic AgentsApoptosisCell ProliferationEnzyme InhibitorsHumansNeoplasmsNeoplastic Stem CellsReceptors, NotchAmyloid Precursor Protein SecretasesAntineoplastic AgentsEnzyme InhibitorsReceptors, Notchcancer stem cellscancer treatmentNotch signalingγ-secretaseγ-secretase inhibitors

Identifiers

PMID33673088
PMCPMC7917912
OpenAlexW3131915944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.